We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-9.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.21B
AUM Growth
-$432M
Cap. Flow
-$92.5M
Cap. Flow %
-4.18%
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$14.4M
2
CNC icon
Centene
CNC
+$8.41M
3
SNY icon
Sanofi
SNY
+$6.73M
4
LLY icon
Eli Lilly
LLY
+$6.66M
5
IQV icon
IQVIA
IQV
+$6.64M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$15.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
3
JNJ icon
Johnson & Johnson
JNJ
+$11.1M
4
MDCO
Medicines Co
MDCO
+$10.3M
5
ELV icon
Elevance Health
ELV
+$9.94M

Sector Composition

Rank Sector Weight
1 Healthcare 95.66%
2 Real Estate 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LTC
76
LTC Properties
LTC
$1.98B
$5.63M 0.25%
182,293
+16,625
+10% +$710K
BMY.RT
77
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$5.6M 0.25%
1,473,710
– –
VTR icon
78
Ventas
VTR
$47.5B
$5.58M 0.25%
208,108
+16,720
+9% +$830K
SBRA icon
79
Sabra Healthcare REIT
SBRA
$5.39B
$5.58M 0.25%
510,660
+44,413
+10% +$819K
PTCT icon
80
PTC Therapeutics
PTCT
$5.78B
$5.39M 0.24%
120,827
+21,500
+22% +$1.08M
ZGNX
81
DELISTED
Zogenix, Inc.
ZGNX
$5.33M 0.24%
215,406
+107,703
+100% +$3.92M
TBPH icon
82
Theravance Biopharma
TBPH
$876M
$5.29M 0.24%
228,836
+111,111
+94% +$2.78M
CERN
83
DELISTED
Cerner Corp
CERN
$5.13M 0.23%
+81,500
New +$5.8M
RETA
84
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.07M 0.23%
35,129
+8,717
+33% +$1.68M
TFX icon
85
Teleflex
TFX
$6.06B
$5.05M 0.23%
17,252
+1,644
+11% +$574K
COR icon
86
Cencora
COR
$61.7B
$4.79M 0.22%
54,107
-61,616
-53% -$5.43M
ALLO icon
87
Allogene Therapeutics
ALLO
$673M
$4.75M 0.21%
244,261
+163,981
+204% +$3.91M
WAT icon
88
Waters Corp
WAT
$39.3B
$4.73M 0.21%
+26,000
New +$5.48M
NKTR icon
89
Nektar Therapeutics
NKTR
$2.47B
$4.7M 0.21%
17,539
-1,373
-7% -$425K
APLS
90
DELISTED
Apellis Pharmaceuticals
APLS
$4.65M 0.21%
173,494
+42,495
+32% +$1.51M
AVDL
91
DELISTED
Avadel Pharmaceuticals
AVDL
$4.5M 0.2%
566,066
-248,522
-31% -$1.91M
XRAY icon
92
Dentsply Sirona
XRAY
$2.86B
$4.46M 0.2%
114,736
-5,000
-4% -$255K
XNCR icon
93
Xencor
XNCR
$1.47B
$4.43M 0.2%
148,231
– –
GWPH
94
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.39M 0.2%
50,101
– –
RARE icon
95
Ultragenyx Pharmaceutical
RARE
$2.46B
$4.33M 0.2%
97,480
– –
ABMD
96
DELISTED
Abiomed Inc
ABMD
$4.29M 0.19%
29,516
-3,200
-10% -$531K
SYNH
97
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$4.26M 0.19%
108,001
-7,841
-7% -$458K
MTD icon
98
Mettler-Toledo International
MTD
$28.5B
$4.23M 0.19%
6,123
+1,900
+45% +$1.42M
LH icon
99
Labcorp
LH
$25.4B
$3.97M 0.18%
36,578
– –
GRTX
100
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$3.96M 0.18%
416,666
– –
2 3
4
5 6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Tekla Capital Management held 227 positions worth $2.21B, down 16% from $2.64B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $92.5M in Q1 2020, closing 10 positions and reducing 76 holdings. Its most notable exit was Medicines Co, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Moderna worth $7.61M.

  • Tekla Capital Management's largest Q1 2020 buy was Moderna: 254,146 shares worth $7.61M.
  • Tekla Capital Management added most to Biogen in Q1 2020, an estimated $14.4M increase.
  • Tekla Capital Management's biggest Q1 2020 reduction was Merck, cutting an estimated $15.5M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2020, selling an estimated $10.3M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.21B portfolio in Q1 2020.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q1 2020.
  • Tekla Capital Management's portfolio value fell 16% quarter-over-quarter to $2.21B.

Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.